12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GDC-0941: Interim Phase Ib data

Interim data from 27 patients in an ongoing, open-label, dose-escalation, U.S. Phase Ib trial showed that once-daily oral GDC-0973 plus GDC-0941 for 21 days followed by 7 days off treatment produced 3 cases of stable disease for...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >